PLRX
Pliant Therapeutics, Inc.
14.16
USD
This page is just a preview of the data found in TrendSpider’s full version
Pliant Therapeutics, Inc. stock is up 1.51% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 November’s closed higher than October. 100% of analysts rate it a buy.
Pliant Therapeutics, Inc. discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins.
